论文部分内容阅读
随美国转基因标识法案通过,实质等同作为转基因作物评价准则已被基本否定。该原则存在实验不足、忽视过程、线性逻辑、缺乏历时等方面的科学方法缺陷。同时,它还蕴涵技术红利价值偏好的非科学缺陷。这会造成人体健康生态环境与市场接受度等安全层面,或基于科学假设、或基于利益推测的不确定性结果。基于此,应从科学风险举证性、评价操作合理性及利害取舍正当性层面来建构转基因作物评价原则体系。
With the adoption of the US GMO Act, substantive equivalence has been basically negated as a criterion for GMO evaluation. This principle has some shortcomings in science, such as under-experimentation, neglecting process, linear logic, lack of duration and so on. At the same time, it also contains non-scientific flaws in the value preference of technology dividend. This can lead to human health and ecological environment and market acceptance of security level, or based on scientific assumptions, or based on the speculation of the uncertainty of the results. Based on this, we should construct the system of evaluation system of GMOs based on the evidence of scientific risk, the rationality of evaluation and the legitimacy of adverse selection.